FractureDetect (FX)
Imagen Technologies, Inc. • Radiology • 07/30/2020
Device Purpose
FractureDetect (FX) is an artificial intelligence-powered software tool designed to assist clinicians in the detection of fractures in adult musculoskeletal radiographs across various anatomical regions and views. By employing supervised deep learning algorithms to analyze DICOM images and provide toggleable annotated overlays, it aims to improve diagnostic accuracy, sensitivity, and specificity in clinical practice.
Summary
FractureDetect (FX) is a computer-assisted detection and diagnosis (CAD) software designed to enhance clinicians' ability to identify fractures in adult musculoskeletal radiographs. It utilizes industry-standard deep learning algorithms for computer vision, specifically supervised deep learning, to analyze DICOM images obtained from sources like PACS systems or imaging devices. The software processes these radiographs and generates a DICOM overlay as its output. This overlay provides clear textual and graphical annotations: "Fracture: DETECTED" along with one or more bounding boxes highlighting potential fracture sites, or "Fracture: NOT DETECTED" if no fractures are identified. Clinicians can easily toggle this informative overlay on or off within their standard PACS viewer, facilitating an unimpeded concurrent review of the original radiographic image. FX supports a comprehensive range of twelve anatomical study types, including ankle, clavicle, elbow, femur, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, and wrist, across various industry-standard radiographic views. The efficacy of FractureDetect (FX) was substantiated through extensive standalone performance testing and a robust clinical reader study. The standalone assessment, conducted on 11,970 radiographs covering all indicated study types and views, demonstrated high performance with an overall sensitivity of 0.951, specificity of 0.893, and an Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) of 0.982. This testing also confirmed FX's consistent accuracy across different anatomical regions and despite potential confounders like image brightness or varying x-ray equipment. Furthermore, a multiple reader, multiple case (MRMC) retrospective clinical study, involving 24 clinical readers and 175 cases, showed that FX significantly improved clinicians' diagnostic accuracy. When aided by FX, reader AUC increased from 0.912 to 0.952, reader sensitivity improved from 0.819 to 0.900, and reader specificity rose from 0.890 to 0.918, thereby confirming its value in enhancing fracture detection.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does FractureDetect (FX) differentiate between acute fractures and old, healed fractures or other bone abnormalities that might mimic fractures on radiographs?; What is the performance variability of FX across different patient demographics (e.g., age, bone density) and varying image quality levels encountered in routine clinical practice?; How does the integration of the FX DICOM overlay into existing PACS workflows impact radiologist reading time and overall efficiency?; What specific deep learning architectural components and training data characteristics contribute to FX's reported sensitivity and specificity, particularly for subtle or complex fracture types?; Are there plans to expand FractureDetect (FX) capabilities to pediatric populations or to detect other musculoskeletal pathologies beyond fractures?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly